Stockscreener 앱 받기
62.21
0.50%
0.31
전일 마감가:
$61.90
열려 있는:
$61.93
하루 거래량:
5.63M
Relative Volume:
2.43
시가총액:
$7.32B
수익:
$947.36M
순이익/손실:
$392.47M
주가수익비율:
20.60
EPS:
3.02
순현금흐름:
$392.71M
1주 성능:
-1.77%
1개월 성능:
-11.92%
6개월 성능:
+14.06%
1년 성능:
+30.06%
1일 변동 폭
$61.28
$62.63
1주일 범위
$61.23
$64.98
52주 변동 폭
$46.26
$79.50
Halozyme Therapeutics Inc Stock (HALO) Company Profile
명칭
Halozyme Therapeutics Inc
전화
(858) 794-8889
주소
12390 EL CAMINO REAL, SAN DIEGO, CA
HALO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
62.21 | 7.28B | 947.36M | 392.47M | 392.71M | 3.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-04 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-10-14 | 업그레이드 | Leerink Partners | Underperform → Market Perform |
| 2025-08-06 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-10 | 재개 | Goldman | Neutral |
| 2025-05-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | 다운그레이드 | Leerink Partners | Market Perform → Underperform |
| 2024-10-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-06-07 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | 개시 | TD Cowen | Outperform |
| 2023-07-24 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-07-24 | 개시 | H.C. Wainwright | Buy |
| 2023-05-10 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | 재개 | Berenberg | Buy |
| 2023-03-16 | 다운그레이드 | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | 재개 | Morgan Stanley | Overweight |
| 2022-11-28 | 개시 | Wells Fargo | Overweight |
| 2022-09-09 | 개시 | Morgan Stanley | Overweight |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2021-06-14 | 개시 | Evercore ISI | Outperform |
| 2021-05-17 | 개시 | SVB Leerink | Outperform |
| 2021-05-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | 재확인 | The Benchmark Company | Buy |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-07-01 | 개시 | The Benchmark Company | Buy |
| 2020-02-05 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | 개시 | Goldman | Buy |
| 2019-11-05 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2018-10-19 | 재개 | Piper Jaffray | Neutral |
| 2018-05-11 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2018-01-24 | 개시 | Goldman | Neutral |
| 2017-10-16 | 재확인 | Piper Jaffray | Overweight |
| 2017-01-06 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2016-11-03 | 개시 | Deutsche Bank | Buy |
| 2015-12-04 | 개시 | Wells Fargo | Outperform |
| 2015-11-18 | 개시 | Citigroup | Buy |
| 2015-09-22 | 개시 | Barclays | Overweight |
| 2015-06-22 | 재확인 | JP Morgan | Overweight |
| 2015-03-03 | 재확인 | UBS | Buy |
| 2015-02-18 | 재확인 | MLV & Co | Buy |
| 2015-01-08 | 재확인 | MLV & Co | Buy |
모두보기
Halozyme Therapeutics Inc 주식(HALO)의 최신 뉴스
BI Asset Management Fondsmaeglerselskab A S Grows Stock Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Stock Report: What catalysts could drive Halozyme Therapeutics Inc stock higherJuly 2025 Intraday Action & Verified Stock Trade Ideas - moha.gov.vn
Halozyme Elects James Lang to Board of Directors - TipRanks
Smart Money: Is Halozyme Therapeutics Inc stock overvalued by current metricsQuarterly Market Summary & High Yield Stock Recommendations - moha.gov.vn
Halozyme Therapeutics, Inc. $HALO Shares Sold by Gabelli Funds LLC - MarketBeat
Halozyme Therapeutics awards performance-based stock units to CEO By Investing.com - Investing.com Canada
Halozyme Approves Stock Grant for CEO Incentive - TipRanks
Halozyme Therapeutics awards performance-based stock units to CEO - Investing.com
(HALO) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term - sharewise.com
Halozyme Therapeutics announces proposed offering of $650M of convertible senior notes due 2031 and 2032 - MSN
Marshall Wace LLP Has $20.24 Million Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
2Xideas AG Sells 62,256 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
James Lang elected to Halozyme Therapeutics board of directors By Investing.com - Investing.com Canada
James Lang elected to Halozyme Therapeutics board of directors - Investing.com
Halozyme Therapeutics Elects New Board Member - TradingView
Jim Lang elected to Halozyme’s board of directors - Investing.com
Jim Lang elected to Halozyme’s board of directors By Investing.com - Investing.com India
Halozyme Therapeutics, Inc. Announces Election of Jim Lang to Board of Directors, Effective December 4, 2025 - marketscreener.com
Halozyme and Quinn Emanuel secure PI against MSD over Keytruda SC - JUVE Patent
Cash per share of Halozyme Therapeutics, Inc. – FWB:RV7 - TradingView
Halozyme wins German injunction blocking Merck’s Keytruda distribution - Indian Pharma Post
Halozyme granted injunction in Germany barring Merck's subcutaneous Keytruda - MSN
Halozyme Therapeutics (HALO): Reassessing Valuation After Strong Year-To-Date Gains And Recent Momentum Slowdown - Yahoo Finance
Norges Bank Makes New Investment in Halozyme Therapeutics, Inc. $HALO - MarketBeat
American Century Companies Inc. Sells 762,886 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
The Healthcare Sector Is Surging. Here's 1 Stock Every Investor Should Have on Their Radar. - Finviz
Why Is Halozyme Therapeutics (HALO) Down 2.2% Since Last Earnings Report? - MSN
Epoch Investment Partners Inc. Sells 195,366 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Analysts Offer Insights on Healthcare Companies: MapLight Therapeutics, Inc. (MPLT) and Halozyme (HALO) - The Globe and Mail
Halozyme Therapeutics (NASDAQ:HALO) Rating Lowered to "Buy" at Wall Street Zen - MarketBeat
Kennedy Capital Management LLC Has $21.60 Million Stake in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) Receives Sell Rating from The Goldman Sachs Group - MarketBeat
Citizens reiterates Market Outperform rating on Halozyme stock amid legal win - Investing.com
Why Halozyme Therapeutics Inc. stock could rally in 20252025 Trade Ideas & Safe Entry Momentum Stock Tips - Newser
Merck suffers a setback over its new Keytruda formulation in Germany - statnews.com
Halozyme Therapeutics Inc RV7 Stock Analysis and ForecastPrice Action Analysis & The Smart Money Is Buying These Picks - earlytimes.in
Halozyme (HALO) Wins Injunction Against Merck in Germany - GuruFocus
How Halozyme Therapeutics Inc. (RV7) stock behaves in tightening cyclesTrade Risk Summary & Expert Curated Trade Setup Alerts - Newser
Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany - Quantisnow
Do Halozyme Therapeutics’ (HALO) Deals And Insider Sales Clarify Or Complicate Its Royalty Story? - Sahm
Halozyme Therapeutics downgraded by Goldman with a new price target - Quantisnow
Goldman Sachs downgrades Halozyme stock to Sell on looming revenue cliff - Investing.com Nigeria
Is Halozyme Therapeutics Inc. stock dividend yield sustainable2025 Support & Resistance & Capital Protection Trading Alerts - Newser
Mackenzie Financial Corp Has $6.16 Million Stock Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics, Inc. $HALO Stock Holdings Lessened by CW Advisors LLC - MarketBeat
Fisher Asset Management LLC Decreases Stock Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Do Halozyme’s (HALO) Upgrades and Deals Justify Insider Sales or Complicate Its Royalty-Driven Story? - Yahoo Finance
Is Halozyme Still Attractive After 2025 Rally and Recent 11% Pullback? - Yahoo Finance
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
What Analysts Now Think Gives Halozyme Therapeutics The Edge Amid Evolving Risks and Rewards - Yahoo Finance
Halozyme Therapeutics Inc (HALO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Halozyme Therapeutics Inc 주식 (HALO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Torley Helen | PRESIDENT AND CEO |
Dec 01 '25 |
Option Exercise |
8.11 |
16,569 |
134,375 |
725,288 |
| Torley Helen | PRESIDENT AND CEO |
Dec 01 '25 |
Sale |
68.92 |
16,569 |
1,141,925 |
708,719 |
| Torley Helen | PRESIDENT AND CEO |
Nov 10 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
| Torley Helen | PRESIDENT AND CEO |
Nov 11 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
| Torley Helen | PRESIDENT AND CEO |
Nov 12 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
| Torley Helen | PRESIDENT AND CEO |
Nov 12 '25 |
Sale |
70.55 |
20,000 |
1,410,990 |
733,719 |
| Torley Helen | PRESIDENT AND CEO |
Nov 11 '25 |
Sale |
69.13 |
20,000 |
1,382,600 |
733,719 |
| Torley Helen | PRESIDENT AND CEO |
Nov 10 '25 |
Sale |
68.72 |
20,000 |
1,374,339 |
733,719 |
| Connaughton Bernadette | Director |
Nov 10 '25 |
Sale |
68.48 |
2,000 |
136,960 |
42,952 |
| Torley Helen | PRESIDENT AND CEO |
Oct 01 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
1.08%
0.91%
자본화:
|
볼륨(24시간):